These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 37062240)

  • 21. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
    Barnes CO; Jette CA; Abernathy ME; Dam KA; Esswein SR; Gristick HB; Malyutin AG; Sharaf NG; Huey-Tubman KE; Lee YE; Robbiani DF; Nussenzweig MC; West AP; Bjorkman PJ
    Nature; 2020 Dec; 588(7839):682-687. PubMed ID: 33045718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An
    Atanasoff KE; Brambilla L; Adelsberg DC; Kowdle S; Stevens CS; Hung CT; Fu Y; Lim R; Tran L; Allen R; Andrew Duty J; Bajic G; Lee B; Tortorella D
    bioRxiv; 2023 Apr; ():. PubMed ID: 37131698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
    Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.
    Liu Z; VanBlargan LA; Bloyet LM; Rothlauf PW; Chen RE; Stumpf S; Zhao H; Errico JM; Theel ES; Liebeskind MJ; Alford B; Buchser WJ; Ellebedy AH; Fremont DH; Diamond MS; Whelan SPJ
    Cell Host Microbe; 2021 Mar; 29(3):477-488.e4. PubMed ID: 33535027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition.
    Kramer KJ; Johnson NV; Shiakolas AR; Suryadevara N; Periasamy S; Raju N; Williams JK; Wrapp D; Zost SJ; Walker LM; Wall SC; Holt CM; Hsieh CL; Sutton RE; Paulo A; Nargi RS; Davidson E; Doranz BJ; Crowe JE; Bukreyev A; Carnahan RH; McLellan JS; Georgiev IS
    Cell Rep; 2021 Oct; 37(1):109784. PubMed ID: 34592170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia.
    Asarnow D; Wang B; Lee WH; Hu Y; Huang CW; Faust B; Ng PML; Ngoh EZX; Bohn M; Bulkley D; Pizzorno A; Ary B; Tan HC; Lee CY; Minhat RA; Terrier O; Soh MK; Teo FJ; Yeap YYC; Seah SGK; Chan CEZ; Connelly E; Young NJ; Maurer-Stroh S; Renia L; Hanson BJ; Rosa-Calatrava M; Manglik A; Cheng Y; Craik CS; Wang CI
    Cell; 2021 Jun; 184(12):3192-3204.e16. PubMed ID: 33974910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
    Hussain A; Hasan A; Nejadi Babadaei MM; Bloukh SH; Chowdhury MEH; Sharifi M; Haghighat S; Falahati M
    Biomed Pharmacother; 2020 Oct; 130():110559. PubMed ID: 32768882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies.
    Rattanapisit K; Bulaon CJI; Khorattanakulchai N; Shanmugaraj B; Wangkanont K; Phoolcharoen W
    PLoS One; 2021; 16(8):e0253574. PubMed ID: 34379620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
    Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2.
    Yu F; Xiang R; Deng X; Wang L; Yu Z; Tian S; Liang R; Li Y; Ying T; Jiang S
    Signal Transduct Target Ther; 2020 Sep; 5(1):212. PubMed ID: 32963228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants.
    Kim JW; Heo K; Kim HJ; Yoo Y; Cho HS; Jang HJ; Lee HY; Ko IY; Woo JR; Cho YB; Lee JH; Yang HR; Shin HG; Choi HL; Hwang K; Kim S; Kim H; Chun K; Lee S
    Antiviral Res; 2023 Apr; 212():105576. PubMed ID: 36870394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.
    Papageorgiou AC; Mohsin I
    Cells; 2020 Oct; 9(11):. PubMed ID: 33105869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection.
    Hwang YC; Lu RM; Su SC; Chiang PY; Ko SH; Ke FY; Liang KH; Hsieh TY; Wu HC
    J Biomed Sci; 2022 Jan; 29(1):1. PubMed ID: 34983527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.
    Tai W; Zhang X; He Y; Jiang S; Du L
    Antiviral Res; 2020 Jul; 179():104820. PubMed ID: 32405117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular Basis of Mink ACE2 Binding to SARS-CoV-2 and Its Mink-Derived Variants.
    Su C; He J; Han P; Bai B; Li D; Cao J; Tian M; Hu Y; Zheng A; Niu S; Chen Q; Rong X; Zhang Y; Li W; Qi J; Zhao X; Yang M; Wang Q; Gao GF
    J Virol; 2022 Sep; 96(17):e0081422. PubMed ID: 36000849
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.